Deadline: 31-Dec-22

AiCuris is accepting applications for AiCubator: A New Way of Collaboration in Anti- infective Area.

AiCuris strongly believes that there is a need to encourage the development of more early projects based on new scientific principles to fill pipeline gaps, tackle AMR and prevent future pandemics.

Benefits

• To promote early ideas that might lead to the next resistant breaking antibiotic or anti-infective, AiCuris has launched the AiCubator, an innovative corporate incubator that provides first-hand and long-term support (up to 3 years) for such research projects from a leader in anti-infective drug development.
• Scientific support.
• Business Expertise.
• Financing Advisory.

Eligible Projects

• Drug discovery project in the following indications:
  • Targeted antiviral therapy, especially for:
    • HBV cure
    • HIV cure
    • BK Virus
    • Epstein-Barr virus
    • Adenovirus
    • Pan-Herpesvirus
    • Norovirus
    • Pandemic preparedness solutions (RSV, pan-respiratory viruses)
    •  Antibacterial (non-small molecule) therapy for:
    • Bloodstream infections
    • Diabetic foot infections
    • Antimicrobial resistance
    • Osteomyelitis
    •  Novel platform approach in infectious diseases.

Criteria

• Project  Minimal Criteria
  • Target identified
  • Preliminary efficacy data
  • Competitive advantage to existing standard of care
• Applicant
  • All applications from companies and scientific groups are welcomed
  • Start-up company
  • Scientific group within a research university/institute
• Application for the AiCubator
  • You are an academic group or a recently formed biotech start-up with antiviral or antibacterial projects?
  • You have identified a new breakthrough mechanism of action with supporting data?
  • You want this invention to become a therapy for patients?
  • You are looking for first-hand support and guidance on your way from a partner with proven experience?

For more information, visit https://www.aicuris.com/57/AiCubator.htm